Bio-Rad Laboratories (NYSE:BIO.B) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Friday.

Separately, TheStreet upgraded Bio-Rad Laboratories from a “c+” rating to a “b-” rating in a research report on Wednesday.

Bio-Rad Laboratories (BIO.B) remained flat at $$255.60 during trading hours on Friday. 2 shares of the stock were exchanged, compared to its average volume of 231. The company has a quick ratio of 2.77, a current ratio of 4.06 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $7,607.42, a P/E ratio of 81.14 and a beta of 0.76. Bio-Rad Laboratories has a twelve month low of $176.50 and a twelve month high of $261.55.

COPYRIGHT VIOLATION WARNING: “Bio-Rad Laboratories (BIO.B) Stock Rating Lowered by ValuEngine” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/12/03/bio-rad-laboratories-bio-b-stock-rating-lowered-by-valuengine.html.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.